Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR1451] to MEF2A
- Suitable for: WB, ICC/IF
- Reacts with: Mouse, Rat, Human
Product nameAnti-MEF2A antibody [EPR1451]
See all MEF2A primary antibodies
DescriptionRabbit monoclonal [EPR1451] to MEF2A
Tested applicationsSuitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human MEF2A aa 450-550. The exact sequence is proprietary.
(Peptide available as
- Human heart, Human skeletal muscle, HeLa and Saos-2 lysate; HeLa cells
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsStore at -20°C. Stable for 12 months at -20°C
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab109420 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 55 kDa.Can be blocked with MEF2A peptide (ab151761).|
|ICC/IF||1/100 - 1/250.|
FunctionTranscriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Also involved in the activation of numerous growth factor- and stress-induced genes. Mediates cellular functions not only in skeletal and cardiac muscle development, but also in neuronal differentiation and survival. Plays diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK signaling in muscle-specific and/or growth factor-related transcription. In cerebellar granule neurons, phosphorylated and sumoylated MEF2A represses transcription of NUR77 promoting synaptic differentiation.
Tissue specificityIsoform MEF2 and isoform MEFA are expressed only in skeletal and cardiac muscle and in the brain. Isoform RSRFC4 and isoform RSRFC9 are expressed in all tissues examined.
Involvement in diseaseDefects in MEF2A might be a cause of autosomal dominant coronary artery disease 1 with myocardial infarction (ADCAD1) [MIM:608320].
Sequence similaritiesBelongs to the MEF2 family.
Contains 1 MADS-box domain.
Contains 1 Mef2-type DNA-binding domain.
modificationsConstitutive phosphorylation on Ser-408 promotes Lys-403 sumoylation thus preventing acetylation at this site. Dephosphorylation on Ser-408 by PPP3CA upon neuron depolarization promotes a switch from sumoylation to acetylation on residue Lys-403 leading to inhibition of dendrite claw differentiation. Phosphorylation on Thr-312 and Thr-319 are the main sites involved in p38 MAPK signaling and activate transcription. Phosphorylated on these sites by MAPK14/p38alpha and MAPK11/p38beta, but not by MAPK13/p38delta nor by MAPK12/p38gamma. Phosphorylation on Ser-408 by CDK5 induced by neurotoxicity inhibits MEF2A transcriptional activation leading to apoptosis of cortical neurons. Phosphorylation on Thr-312, Thr-319 and Ser-355 can be induced by EGF.
Sumoylation on Lys-403 is enhanced by PIAS1 and represses transcriptional activity. Phosphorylation on Ser-408 is required for sumoylation. Has no effect on nuclear location nor on DNA binding. Sumoylated by SUMO1 and, to a lesser extent by SUMO2 and SUMO3. PIASx facilitates sumoylation in postsynaptic dendrites in the cerebellar cortex and promotes their morphogenesis.
Acetylation on Lys-403 activates transcriptional activity. Acetylated by p300 on several sites in diffentiating myocytes. Acetylation on Lys-4 increases DNA binding and transactivation (By similarity). Hyperacetylation by p300 leads to enhanced cardiac myocyte growth and heart failure.
Proteolytically cleaved in cerebellar granule neurons on several sites by caspase 3 and caspase 7 following neurotoxicity. Preferentially cleaves the CDK5-mediated hyperphosphorylated form which leads to neuron apoptosis and transcriptional inactivation.
- Information by UniProt
- ADCAD1 antibody
- MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) antibody
- MEF2 antibody
All lanes : Anti-MEF2A antibody [EPR1451] (ab109420) at 1/10000 dilution
Lane 1 : Human heart lysate
Lane 2 : Human skeletal muscle lysate
Lane 3 : HeLa cell lysate
Lane 4 : Saos-2 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 55 kDa
ab109420, at 1/100 dilution, staining MEF2A in HeLa cells by Immunohistochemistry.
ab109420 has been referenced in 4 publications.
- Payne S et al. Regulatory pathways governing murine coronary vessel formation are dysregulated in the injured adult heart. Nat Commun 10:3276 (2019). PubMed: 31332177
- Carmichael RE et al. MEF2A regulates mGluR-dependent AMPA receptor trafficking independently of Arc/Arg3.1. Sci Rep 8:5263 (2018). PubMed: 29588465
- Zhu B et al. The transcription factor MEF2A plays a key role in the differentiation/maturation of rat neural stem cells into neurons. Biochem Biophys Res Commun 500:645-649 (2018). PubMed: 29678571
- Sacilotto N et al. MEF2 transcription factors are key regulators of sprouting angiogenesis. Genes Dev 30:2297-2309 (2016). PubMed: 27898394